Opinion
Video
Making the Most of New Data in MPN, Leukemia, and GVHD From ASH 2023: Drs Ponce and Hobbs
Author(s):
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Today-
We are reporting from the 2023 ASH Annual Meeting!
Get ready for highlights of some of the top news presented each day during the meeting—and soon we’ll speak with Drs Gabriela Hobbs and Doris Ponce to discuss some new data in myeloproliferative neoplasms and leukemia as well as graft-vs-host disease.
Welcome to OncLive News Network! I’m Caroline Seymour.
Up-front treatment with the combination of navitoclax and ruxolitinib (Jakafi) significantly reduced spleen volume by 35% or more at week 24 (SVR35W24) compared with ruxolitinib plus placebo for patients with myelofibrosis; however, a significant difference was not observed in total symptom score (TSS) version 4.0 between the arms, according to findings from the phase 3 TRANSFORM-1 study.
The all-oral combination of revumenib (SNDX-5613), decitabine/cedazuridine, and venetoclax (Venclexta) demonstrated a 100% objective response rate (ORR) as well as safety for patients with relapsed/refractory acute myeloid leukemia (AML) enrolled in the small phase 1/2 SAVE study.
Primary outcomes from the randomized, phase III REACH3 (NCT03112603) study were confirmed in the 3-year updated analysis, demonstrating sustained efficacy with ruxolitinib vs best available therapy in patients with chronic graft-vs-host-disease, though adverse effects were higher with the JAK inhibitor due to prolonged exposure to treatment.
Finally, in results from the phase 2 AGAVE-201 trial (NCT04710576), treatment with axatilimab produced robust antitumor activity and durable responses in all 3 dose cohorts evaluated in patients with refractory and heavily pretreated chronic GVHD, with the highest response rate and least toxicity observed at the 0.3 mg/kg every-2-week dose.
Please be sure to check out more of our coverage from the 2023 ASH Annual Meeting at OncLive.com.
That’s all for today. Tomorrow, we’ll sit down with Drs Hayder Saeed and C. Ola Landgren, who will share their perspectives on critical research in lymphoma and multiple myeloma.
Thank you for watching OncLive News Network: On Location, I’m Caroline Seymour.
